SEVERE WX : Freeze Warning View Alerts

Hemophilia trial finds promising cure

A gene-therapy trial by London researchers has seen remarkable success in finding a long-term cure for hemophilia A....

Posted: Dec 14, 2017 8:05 PM
Updated: Dec 14, 2017 8:05 PM

A gene-therapy trial by London researchers has seen remarkable success in finding a long-term cure for hemophilia A.

The trial, by researchers at Barts Health NHS (National Health Service) Trust and Queen Mary University of London, used gene therapy to inject one dose of a missing gene in patients with the condition, and the gene continued functioning in the body for more than a year.

Hemophilia is a hereditary genetic condition

Patients do not have the gene allowing blood to clot

There is no known permanent cure

New gene-therapy trial finds long-term cure

This is the first successful gene therapy to treat the condition.

Hemophilia is a hereditary genetic disorder, mostly affecting men, causing people to have low levels of clotting factor VIII, needed for their blood to clot.

Lack of the protein factor results in excessive bleeding from even minor injuries and can cause internal bleeding, which is life-threatening.

To date, there is no permanent cure for hemophilia, and patients have to take multiple weekly injections of clotting factor VIII to prevent and control bleeding.

"I'm very optimistic that we can deliver long-term treatment benefits," said John Pasi, Haemophilia Centre director at Barts Health NHS Trust and lead author of the study published Saturday in the New England Journal of Medicine.

"To say that it's going to be an absolute cure would be a bit rash, but I'm extremely optimistic that we will follow these patients and hopefully see great results continuing."

Record success in trial

More than 400,000 people around the world are estimated to suffer from hemophilia A, which is six times as common as hemophilia B, according to an accompanying editorial.

Type A sufferers lack factor VIII clotting protein, while those with type B lack factor IX.

In the UK, where the study was conducted, around 2,000 people suffer from severe hemophilia A.

During the trial, 13 patients received high-dose injections containing a copy of the gene that in turn codes the missing clotting protein. The patients were followed for 19 months to monitor success.

All 13 patients were off their treatment one year on, while 11 showed near-normal levels of the clotting protein and the remaining two showed stable levels, said Pasi.

The only side-effect Pasi said his team noticed was a sudden spike in liver enzymes, by almost three times. This did not result in external symptoms and eventually stabilized.

"We're trying to understand why [the spike] might happen but it's something that's fairly well recognized across gene therapy," he adds.

Breakthrough in curing hemophilia

Treatiing people with hemophilia A is very expensive, and the patients themselves face numerous lifestyle hurdles.

"The clotting factors are incredibly expensive, costing about -100,000 ($130,000) per patient per year, without ancillary care," said Simon Waddington, reader in gene transfer technology at University College London, who was not involved in the trial.

"They inject the factors and of course, you have peaks and drops in the circulatory levels of the factors so they are at risk of bleeding through their joints when the levels drop out."

With gene therapy, he explained, a single injection could provide the steady levels needed, and be more cost-effective.

Jake Omer, a father of two, was diagnosed with hemophilia A when he was two years old and suffers from arthritis in his ankles because of repeated internal bleeding. Participation in the trial has dramatically changed his life.

"I now have hope for my future. It is incredible to now hope that I can play with my kids, kick a ball around and climb trees well into my kids' teenage years and beyond," he said in a statement.

Gene therapy has high success

"Gene therapy has now turned the corner completely in terms of showing incredible results in a variety of different early clinical trials," said Waddington.

"For this trial, it is delightful that such high levels [of success] have been achieved because factor VIII has always been considered a much tougher target using gene therapy... [because it is a] more difficult molecule to manipulate."

Another common side-effect of gene therapy is an immune response to the injections that some patients have, he added. This can be countered using steroids or immune suppressants, to prevent the body from flushing the gene out.

Pasi regards durability as the big question in this trial -- the only other hemophilia trial on humans, done seven years ago, has continued to show stability, he said, which makes him hopeful.

The team is in talks with BioMarin Pharmaceutical, which manufactured the injection for this study, for investment in larger facilities.

They aim to expand to patients in Europe, the US, Africa and South America, with 60 new patients in the next trial.

Lafayette
Cloudy
36° wxIcon
Hi: 50° Lo: 30°
Feels Like: 30°
Kokomo
Partly Cloudy
31° wxIcon
Hi: 46° Lo: 24°
Feels Like: 25°
Rensselaer
Cloudy
32° wxIcon
Hi: 46° Lo: 31°
Feels Like: 26°
Lafayette
Cloudy
36° wxIcon
Hi: 47° Lo: 29°
Feels Like: 30°
Danville
Cloudy
34° wxIcon
Hi: 50° Lo: 30°
Feels Like: 27°
Frankfort
Cloudy
30° wxIcon
Hi: 49° Lo: 26°
Feels Like: 30°
Frankfort
Cloudy
30° wxIcon
Hi: 46° Lo: 25°
Feels Like: 30°
Monticello
Cloudy
32° wxIcon
Hi: 48° Lo: 27°
Feels Like: 32°
Monticello
Cloudy
32° wxIcon
Hi: 47° Lo: 30°
Feels Like: 32°
Logansport
Mostly Cloudy
° wxIcon
Hi: 46° Lo: 25°
Feels Like: °
Snow to Two Nights of Freezing...
WLFI Radar
WLFI Temps
WLFI Planner

Indiana Coronavirus Cases

Data is updated nightly.

Cases: 709455

Reported Deaths: 13234
CountyCasesDeaths
Marion967001722
Lake51824946
Allen39279673
Hamilton34580406
St. Joseph34207541
Elkhart27376432
Vanderburgh22091394
Tippecanoe21886212
Porter17952299
Johnson17556374
Hendricks16837310
Clark12705190
Madison12358337
Vigo12226244
Monroe11484166
LaPorte11175204
Delaware10374184
Howard9677211
Kosciusko9152114
Hancock8000139
Bartholomew7896155
Warrick7698155
Floyd7567176
Wayne6910198
Grant6852171
Boone6562100
Morgan6404138
Dubois6086117
Marshall5792109
Dearborn570776
Cass5689102
Henry5582101
Noble542683
Jackson493970
Shelby479895
Lawrence4347118
Gibson429089
Harrison428970
Clinton420253
Montgomery418386
DeKalb412184
Whitley381439
Huntington380180
Miami373265
Knox367089
Steuben366657
Putnam353360
Jasper351346
Wabash347878
Adams338153
Ripley334968
Jefferson313280
White308554
Daviess289699
Wells286681
Decatur279192
Fayette277362
Greene270785
Posey269133
Scott261553
LaGrange254270
Clay253545
Randolph235880
Washington231131
Spencer228031
Jennings225147
Fountain208945
Sullivan207942
Starke205452
Owen192656
Fulton192140
Jay186429
Carroll186120
Perry181036
Orange178053
Rush170824
Vermillion166143
Franklin165635
Tipton161043
Parke144616
Blackford133931
Pike130334
Pulaski114045
Newton104234
Brown100740
Crawford97914
Benton97113
Martin82915
Warren80115
Switzerland7698
Union70110
Ohio56011
Unassigned0408

COVID-19 Important links and resources

As the spread of COVID-19, or as it's more commonly known as the coronavirus continues, this page will serve as your one-stop for the resources you need to stay informed and to keep you and your family safe. CLICK HERE

Closings related to the prevention of the COVID-19 can be found on our Closings page.

Community Events